Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Evaluation of Sentinel Node Policy in Early Stage Endometrial Carcinomas at Intermediate and High Risk of Recurrence. (SENTIRAD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02598219
Recruitment Status : Active, not recruiting
First Posted : November 5, 2015
Last Update Posted : September 18, 2019
Sponsor:
Collaborators:
National Cancer Institute, France
Institut National de la Santé Et de la Recherche Médicale, France
Canceropôle Nord Ouest
Information provided by (Responsible Party):
Centre Oscar Lambret

Brief Summary:
The aim of this study is to evaluate the sentinel node policy in early stage endometrial carcinomas at intermediate and high risk of recurrence (by comparing the sentinel node policy to current initial staging protocols).

Condition or disease Intervention/treatment Phase
Endometrial Carcinoma Drug: Pre-operative SN mapping with radionucleide Drug: Intra-operative SN mapping with patent V blue dye Drug: Intra-operative SN mapping with indocyanin green Procedure: Full bilateral laparoscopic lymphadenectomy and Hysterectomy Procedure: Current initial staging protocols Phase 3

Detailed Description:
  1. Routine exams required for diagnosis:

    • Endometrioid biopsy or product of a dilatation-curettage under hysteroscopy for diagnosis of histologic typing
    • Tumor assessment: Lombopelvic MRI (1.5 or 3T) with gadolinium injection, studied by steady and dynamic sequences. US and CT-Scan in case of intolerance to MRI should be discussed. FDG-PET may be an option.
  2. Tumor board: The completed chart will be reviewed to confirm the risk group and indication.
  3. Complete physical and gynecological examination by surgical oncologist followed by a consultation of anesthesiology to confirm the operability of patient.
  4. Informed and signed consent form.
  5. Study baseline assessment.

    Then,

  6. Surgery should be performed within a maximum of 4 weeks from the first consultation, according arm allocated:

    Arm A: Sentinel node policy*

    Arm B:

    • Bilateral pelvic lymphadenectomy (intermediate risk endometrioid)
    • Or Ilio-infrarenal paraaortic lymphadenectomy (high risk endometrioid)
    • Or Pelvic + paraaortic lymphadenectomies (high risk non endometrioid)*

      • along with a peritoneal staging for each arm (cytology, random biopsies, infracolic omentectomy)
  7. Second tumor board: after definitive pathological results of the hysterectomy-annexectomy and node (sentinel or not) specimens.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 240 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Randomized Study Comparing Sentinel Node (SN) Policy to Current French Initial Staging Protocols in Early Stage Endometrial Carcinomas at Intermediate and High Risk of Recurrence
Actual Study Start Date : November 2015
Estimated Primary Completion Date : November 2021
Estimated Study Completion Date : November 2022

Arm Intervention/treatment
Experimental: Pre-operative SN mapping with radionucleide

1 Pre-operative Sentinel Node (SN) mapping with Nanocis or Nanocoll or Rotop-nanoHSA

2- Intra-operative SN mapping with patent V blue dye, or Intra-operative SN mapping with indocyanin green for patients with known hypersensitivity, allergy to patent V blue dye

3- Full bilateral laparoscopic lymphadenectomy and Hysterectomy: If bilateral SN are detected, all positive SN are removed, then the surgeon proceeds to a total hysterectomy.

If unilateral SN are detected, surgeon will complete intervention with pelvic LN dissection on the opposite side, in accordance with risk group definition (ex: omentectomy for high-risk non endometrioid carcinomas).

If non SN are detected, surgeon will proceed to a total hysterectomy, a bilateral salpingo-oophorectomy, a complete and bilateral pelvic LND with more enlarged dissection regardless the pathology

Drug: Pre-operative SN mapping with radionucleide
  1. Preparation : four 1ml syringe (Nanocis, or Nanocoll, or Rotop-nanoHSA) are prepared per patient, each containing a total activity 10 MBq if the injection is planned the same day of surgery and in the operative theater OR each containing a total activity 30MBq if the injection is performed the day before the surgery.
  2. Intracervical injection is performed by the surgeon, no more than 3-24 hours before surgery : 4 submucous injections with the filtered radiocolloid at 3, 6, 9 and 12 o'clock positions. Each injection if performed at 2 mm of depth for a total activity of 40 MBq or a total activity of 120 MBq is the surgery is planned the day after the injection.
  3. Sentinel Node detection by planar scintigraphy at 1 and 3h (if no detection at 1 hour), or by SPECT-CT imaging if available.
Other Name: Pre-operative Sentinel Node

Drug: Intra-operative SN mapping with patent V blue dye
  1. Patent blue V dye are diluted with saline sterile solution to obtain 4ml of 50%. Four 1ml syringe, each containing a 50% patent blue dye solution, are prepared per patient.
  2. Intracervical injection is performed by the surgeon. after anesthesis induction and incising the skin,under laparoscopic / laparotomy control to detect intraperitoneal injection of the tracer. Sub-mucous injections are performed with 50% diluted dye at 3 and 9 o'clock positions. At each positions : 1ml is injected deep into the stroma of the cervix (1cm), another 1ml is injected superficially (at 2mm depth). The time between the injection of the dye and the search for the SN must be as shortest as possible.
  3. SN are detected by direct visualization of blue colored lymphatics and node
Other Name: Intra-operative SN mapping

Drug: Intra-operative SN mapping with indocyanin green

1: Infracyanine powder is diluted in aqueous sterile water to obtain 4ml with a concentration of 1.25 mg/mL. Four 1ml syringe, each containing a 1.25 mg/mL Infracyanine dye solution, are prepared per patient.

2- Intracervical injection is performed by the surgeon, after anesthesis induction and incising the skin,under laparoscopic / laparotomy control to detect intraperitoneal injection of the tracer. Sub-mucous injections are performed with 50% diluted dye at 3 and 9 o'clock positions. At each positions : 1ml is injected deep into the stroma of the cervix (1cm), another 1ml is injected superficially (at 2mm depth). The time between the injection of the dye and the search for the SN must be as shortest as possible

3- SN detection by near-infrared fluorescence imaging

Other Name: Intra-operative Sentinel Node (SN) mapping with Infracyanine

Procedure: Full bilateral laparoscopic lymphadenectomy and Hysterectomy
  • Bilateral pelvic lymphadenectomy (intermediate risk endometrioid)
  • Or Ilio-infrarenal paraaortic lymphadenectomy (high risk endometrioid)
  • Or Pelvic + paraaortic lymphadenectomies (high risk non endometrioid)
Other Name: Full bilateral lymphadenectomy

B : Current initial staging protocols
Current initial staging protocols
Procedure: Current initial staging protocols
Current French initial staging protocols




Primary Outcome Measures :
  1. Morbidity [ Time Frame: Up to 3 after surgery ]

    Per-operative morbidity will be assessed during surgery according to the Oslo classification of intraoperative unfavourable incidents.

    Early post-operative morbidity will be assessed up to 30 days and scored according to Clavien-Dindo scale. Distant complications, beyond day 30 for patients with no indication of a secondary surgical staging (e.g. secondary paraaortic dissection for pelvic pN1) will be evaluated in accordance with the NCI-CTCAE scale v4.03



Secondary Outcome Measures :
  1. Rate of detected sentinel node [ Time Frame: During surgery ]
    number of patients with ≥ 1 Sentinel Node (SN) / total number of explored patients, and bilaterality

  2. Rate of pN1 [ Time Frame: an average of 1 month after surgery ]
    n pN1 / total N

  3. Disease free survival [ Time Frame: Up to 5 years after surgery ]
    Time from the date of randomization to the first documentation of local, regional or distant disease or death, whichever occurs first.

  4. Overall survival [ Time Frame: Up to 5 years after surgery ]
    Time from the date of randomization to the date of death (indicate if the death is due to disease progression or not).

  5. Pronostic value of L1CAM on the risk of reccurrence [ Time Frame: an average of 1 month after surgery ]
    A standard staining with HES is carried out in a systematic manner as well as immunohistochemistry with polyclonal anti-L1CAM. If 10% or more of the tumor cells showed L1CAM staining, the sample is rated positive. The rate of L1CAM positive sample will be further correlated with the node involvement and disease recurrence.

  6. Proteomic signature of positive SN [ Time Frame: an average of 1 year after surgery ]
    Detection of SN involvement with proteomics



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Patients with early endometrial carcinoma with early FIGO clinical stage I-II (clinical examination, abdomino-pelvic MRI/Ultrasound - or CT scan if MRI not possible - and endometrial biopsy or curettage), then stratification of the recurrence risk as defined by last European Society for Medical Oncology (ESMO) guidelines :

    • Intermediate-risk endometrioid (type 1): FIGO stage IA/T1a grade 3, or IB grade 1 or 2
    • Or High risk endometrioid (type 1) : FIGO stage IB/T1b grade 3, or II grade 1 or 2 or 3
    • Or High risk non endometrioid (type 2) : FIGO stages I-II
  2. Without any suspicious pelvic, paraaortic, distant node at preoperative MRI
  3. Age ≥ 18 years
  4. Performance status (OMS) ≤ 2
  5. No contraindication to surgery
  6. Absence of known hypersensitivity to colloidal rhenium sulphide and technetium (nanocolloid) or one of its excipients, to human albumin preparations, to Nanocoll® and Rotop-nanoHSA® and their excipients, to injectable dyes (blue dye or indocyanine green if available) or one of their excipients, to triphenylmethane derivatives
  7. Signed and dated informed consent
  8. Effective contraception for patients with reproductive potential
  9. Patient affiliated with a health insurance system

Exclusion Criteria:

  1. Preoperative workup with :

    • Previous hysterectomy (by nature, this trial cannot be offered as a secondary staging procedure)
    • non carcinoma (for example sarcoma, trophoblastic tumor)
    • Low-risk endometrioid carcinoma as defined by the ESMO: 2009 FIGO stage IA grade 1-2
    • Metastatic disease at preoperative workup
    • Suspicious adenopathy at preoperative workup
  2. Pregnant and/or breastfeeding woman
  3. No understanding of the trial
  4. Patient deprived of liberty or in guardianship
  5. Inexperience of the trial site in pelvic sentinel node detection

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02598219


Locations
Layout table for location information
France
Polyclinique Urbain V
Avignon, France, 84036
Centre Hospitalier Régional Universitaire
Besançon, France, 25000
Institut Bergonié
Bordeaux, France, 33076
Centre Jean Perrin
Clermont-Ferrand, France, 63011
CHU Clermont-Ferrand
Clermont-Ferrand, France
Centre Georges François Leclerc
Dijon, France
Centre Oscar Lambret
Lille, France, 59020
Hôpital Jeanne de Flandres, CHRU Lille
Lille, France, 59037
Hôpital Mère-Enfant, CHU Limoges
Limoges, France, 87042
Centre Léon Bérard
Lyon, France, 69008
Institut Paoli Calmettes
Marseille, France, 13273
ICM Val d'Aurelle
Montpellier, France, 34298
Hôpital La Pitié-Salpêtrière
Paris, France, 75013
Hôpital Européen Georges Pompidou
Paris, France, 75015
Hôpital Tenon
Paris, France, 75020
Institut Jean Godinot
Reims, France, 51056
Institut de Cancérologie de l'Ouest, René Gauducheau
Saint-Herblain, France, 44805
Centre Paul Strauss
Strasbourg, France, 67065
Centre Hospitalier Universitaire
Strasbourg, France, 67098
Institut Claudius Regaud
Toulouse, France, 31059
Institut Gustave Roussy
Villejuif, France, 94800
Sponsors and Collaborators
Centre Oscar Lambret
National Cancer Institute, France
Institut National de la Santé Et de la Recherche Médicale, France
Canceropôle Nord Ouest
Investigators
Layout table for investigator information
Study Director: Eric LEBLANC, MD Centre Oscar Lambret
Study Director: Hélène GAUTHIER, MD Centre Oscar Lambret

Layout table for additonal information
Responsible Party: Centre Oscar Lambret
ClinicalTrials.gov Identifier: NCT02598219     History of Changes
Other Study ID Numbers: SENTIRAD-1502
First Posted: November 5, 2015    Key Record Dates
Last Update Posted: September 18, 2019
Last Verified: September 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Centre Oscar Lambret:
Sentinel node
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma
Endometrial Neoplasms
Recurrence
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Disease Attributes
Pathologic Processes
Uterine Neoplasms
Genital Neoplasms, Female
Urogenital Neoplasms
Neoplasms by Site
Uterine Diseases
Genital Diseases, Female